Phase 4 study where patient has severe dry eyes that is not controlled by Cyclosporine (0.05%) (Restasis). Subject enrollment will be classified by evidence of DED. Solution will be used to treat the patient (Cequa), in eahc eye twice a day for twelve weeks. Cequa is expected to show improved benefits and reduction of severe dry eye disease.
Criteria:1. Must be 18
2. Must provide written consent
3. Must have a history of clinical diagnosis of DED
4. Must have a total CSF score of over 6
5. Must have a BCVA at 20/200 or better in both eyes
6. Must be willing to discontinue use of all dry eye therapy
7. Women of childbearing potential must have a negative urine pregnancy test
8. Must agree to use contraception